This multi-institutional clinical trial, titled AIM-NIVO (Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies), is a phase 1b study to assess the overall safety of using anti-PD-1 in patients with various autoimmune diseases, including SLE (NCT03816345). Here, PDCD1 is linked to autoimmune disease.